NGeneBio Balance Sheet Health
Financial Health criteria checks 4/6
NGeneBio has a total shareholder equity of ₩13.1B and total debt of ₩11.5B, which brings its debt-to-equity ratio to 88%. Its total assets and total liabilities are ₩40.5B and ₩27.5B respectively.
Key information
88.0%
Debt to equity ratio
₩11.49b
Debt
Interest coverage ratio | n/a |
Cash | ₩16.48b |
Equity | ₩13.06b |
Total liabilities | ₩27.48b |
Total assets | ₩40.54b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A354200's short term assets (₩21.3B) do not cover its short term liabilities (₩24.9B).
Long Term Liabilities: A354200's short term assets (₩21.3B) exceed its long term liabilities (₩2.6B).
Debt to Equity History and Analysis
Debt Level: A354200 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A354200's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A354200 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A354200 has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 2.6% each year.